维普期刊资源整合服务平台（V6.5）

192篇 您的检索式：作者名="Wilhelm SM"

选中清除导出查看参考文献查看引证文献引用追踪共10页首页上一页第1页下一页末页 /10 跳转

	题名	作者	年代	出处	被引量
1	BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis 显示文摘	Wilhelm SM Carter C Tang L	2004	Cancer Res2004，64，19：	1
2	BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/ MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis 显示文摘	Wilhelm SM Carter C Tang LY	2004	Cancer Res2004，64，：	1
3	Preclinical overview of sorafenib,a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling显示文摘	Wilhelm SM Adnane L Newell P		0，，10：	1
4	Teduglutide for the Treatment of Short Bowel Syndrome显示文摘	Wilhelm SM Lipari M Kulik JK	2014	Ann Pharmacother2014，48，9：	1
5	BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis显示文摘	Wilhelm SM Carter C Tang L	2004	Cancer Res2004，64，19：	1
6	Guidelines for iden- tification and management of outpatient percutaneous en- doscopic gastrostomy tube placement 显示文摘	Wilhelm SM Ortega KA Stellato TA	2010	Am J Surg2010，199，3：	1
7	Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling 显示文摘	Wilhelm SM Adnane L Newell P	2008	Mol Cancer Ther2008，7，：	1
8	Preclinical overview of sorafenib,a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling显示文摘	Wilhelm SM Adnane L Newell P	2008	Mol Cancer Ther2008，7，10：	1
9	BAY 43-9006 ex- hibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kina- ses involved in tumor progression and angiogenesis 显示文摘	Wilhelm SM Carter C Tang L	2004	Cancer Res2004，64，19：	1
10	BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis显示文摘	Wilhelm SM Carter C Tang LY		0，，19：	1
11	BAY 43-9006 exhibits broad Spectrum oral antitumor activity and targets the RAS/RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis显示文摘	Wilhelm SM Carter C Tang L	2004	Cancer Res2004，64，19：	1
12	BAY 43-9006 exhibits broad spectnun oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis 显示文摘	Wilhelm SM Carter C Tang L	2004	Cancer Res2004，64，19：	1
13	Evaluation and management of incidental thyroid nodules in patients with another primary malignancy显示文摘	Wilhelm SM Robinson AV Krishnamurthi SS	2007	Surgery2007，142，4：	1
14	BAY 43-9006 exhibits broad spectrum oral anfitumor activity and targets the RAF/MEK/ ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis显示文摘	Wilhelm SM Carter C Tang L	2004	Cancer Res2004，64，19：	1
15	BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAS/RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis显示文摘	Wilhelm SM Carter C Tang L	2004	Cancer Res2004，64，19：	1
16	BAY 43 90(/6 exhibits broad spectrum oral antitumor activity and targets the RAF/ MEK/ERK path-way and receptor tyrosine kinases involved in tumor progression and angiogenesis显示文摘	Wilhelm SM Carter C Tang L	2004	Cancer Res2004，64，：	1
17	BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis显示文摘	Wilhelm SM Carter C Tang L	2004	Cancer Res2004，64，19：	1
18	BAY 4329006 ex- hibits broad spectrum oral antitumor activity and targets the RAF /MEK/ERK pathway and receptor tyrosine kinases involved in tu- mor progression and angiogenesis 显示文摘	WILHELM SM CARTER C TANG L	2004	Cancer Res2004，64，：	1
19	BAY43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis 显示文摘	Wilhelm SM Carter C Tang L	2004	Cancer Res2004，64，19：	1
20	BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets theRAF/MEK/ERKpathway and receptor tyrosine kinases involved in tumor progression and angiogenesis显示文摘	Wilhelm SM Carter C Tang L	2004	Cancer Res2004，64，19：	1

返回顶部每页显示：

共10页首页上一页第1页下一页末页 /10 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示